- Home
- TGTX vs MAC Comparison
TGTX vs MAC Comparison
Compare TGTX & MAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGTX | MAC |
|---|---|---|
| Founded | 1993 | 1964 |
| Country | United States | United States |
| Employees | N/A | 2845 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.9B |
| IPO Year | 2008 | 1994 |
Fundamental Metrics
Financial Performance| Metric | TGTX | MAC |
|---|---|---|
| Price | $26.92 | $18.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $50.67 | $20.25 |
| AVG Volume (30 Days) | 1.4M | ★ 2.0M |
| Earning Date | 05-29-2026 | 05-20-2026 |
| Dividend Yield | N/A | ★ 3.51% |
| EPS Growth | ★ 1746.67 | 11.36 |
| EPS | ★ 2.77 | N/A |
| Revenue | $2,785,000.00 | ★ $1,013,983,000.00 |
| Revenue This Year | $48.75 | N/A |
| Revenue Next Year | $25.01 | $4.34 |
| P/E Ratio | $10.15 | ★ N/A |
| Revenue Growth | N/A | ★ 10.43 |
| 52 Week Low | $25.37 | $12.48 |
| 52 Week High | $46.48 | $20.93 |
Technical Indicators
Market Signals| Indicator | TGTX | MAC |
|---|---|---|
| Relative Strength Index (RSI) | 33.88 | 42.43 |
| Support Level | $25.37 | $17.77 |
| Resistance Level | $32.77 | $18.95 |
| Average True Range (ATR) | 1.22 | 0.62 |
| MACD | -0.20 | -0.18 |
| Stochastic Oscillator | 3.49 | 22.45 |
Price Performance
Historical ComparisonAbout TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and seven other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $867 sales per square foot over the 12 months ended in September 2025.